This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Scilex Holding Co. is a biopharmaceutical company that develops and commercializes non-opioid pain management therapeutics. Its portfolio includes FDA-approved products ZTlido (lidocaine topical system) for postherpetic neuralgia and Gloperba (colchicine oral solution) for gout flares. The company’s pipeline includes SP-102 (a corticosteroid for sciatica) and other candidates targeting acute and chronic pain.
The company’s development and regulatory process for its pharmaceutical products inherently involves animal testing. Preclinical studies to establish safety, efficacy, and pharmacokinetics, which are required by the FDA for investigational new drug applications and new drug approvals, are conducted in animal models. For example, the development of its lead candidates would involve standard animal testing protocols. This places the company within the broad commercial exploitation of animals for biomedical research and product development, which falls under the animal_exploitation exclusion category.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.